ETF profile for Vaneck Biotech ETF (BBH) from the issuer: top holdings, net assets, expense ratio and shares outstanding.
BBH ETF Profile
| Family: |
Van Eck Associates Corporation |
| Name: |
VanEck Biotech ETF |
|
|
| Inception Date: |
20-Dec-2011 |
| Termination Date: |
|
| Investment Objective: |
VanEck Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. |
|
|
| Prospectus |
|
|
|
| Top 10 Holdings |
|
|
| Amgen Inc |
AMGN |
16.3440% |
| Gilead Sciences Inc |
GILD |
13.6020% |
| Vertex Pharmaceuticals Inc |
VRTX |
8.0443% |
| Regeneron Pharmaceuticals Inc |
REGN |
6.7356% |
| Moderna Inc |
MRNA |
6.5147% |
| Natera Inc |
NTRA |
4.8858% |
| Iqvia Holdings Inc |
IQV |
4.4793% |
| Illumina Inc |
ILMN |
4.1231% |
| Argenx Se |
ARGX |
4.1230% |
| Revolution Medicines Inc |
RVMD |
3.7485% |
|
Top 10 Holdings Weight: |
72.6% |
| Number of Holdings: |
26 |
| Shares Outstanding: |
2,036,502 |
| Total Net Assets: |
515,790,368 |
| NAV: |
253.31 |
| Net Expense Ratio: |
0.35% |
|
|
| Asset Class: |
Equities (Stocks) |
| Developed or Emerging: |
Developed Market Funds |
| Country: |
|
| Region: |
|
| Strategy: |
|
| Currency: |
|
| Commodity: |
|
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Dividend Type: |
|
| Tax Exempt State: |
|
| Maturity Duration: |
|
| Market Cap: |
Broad Market / Multi-Cap |
| Credit Quality: |
|
| Mortgage Bond Types: |
|
| Bond Type: |
|
| Gov't Bond Types: |
|
| Reit Type: |
|
| Leverage Direction/Factor: |
|
| Is Currency Hedged: |
No |
| US or Ex-US: |
Global |
